Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.775 GBX | -6.06% | -8.82% | -8.82% |
04-25 | N4 Pharma strikes partnership deal for intracellular delivery | AN |
04-23 | N4 Pharma loss widens but "great optimism" remains | AN |
Sales 2021 | - | Sales 2022 | - | Capitalization | 4.32M 5.4M 7.39M |
---|---|---|---|---|---|
Net income 2021 | -1M -1.25M -1.71M | Net income 2022 | -1M -1.25M -1.71M | EV / Sales 2021 | - |
Net cash position 2021 | 1.78M 2.23M 3.05M | Net cash position 2022 | 1.92M 2.4M 3.28M | EV / Sales 2022 | - |
P/E ratio 2021 |
-5.22
x | P/E ratio 2022 |
-3.35
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 77.72% |
Latest transcript on N4 Pharma Plc
1 day | -6.06% | ||
1 week | -8.82% | ||
Current month | +19.23% | ||
1 month | +14.81% | ||
3 months | -11.43% | ||
6 months | -8.82% | ||
Current year | -8.82% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 59 | 13-12-31 | |
David Templeton
CTO | Chief Tech/Sci/R&D Officer | - | 17-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 46 | 20-07-13 | |
Founder | 59 | 13-12-31 | |
Chris Britten
CHM | Chairman | - | 19-05-19 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.775 | -6.06% | 611,345 |
24-04-25 | 0.825 | 0.00% | 3,285,001 |
24-04-24 | 0.825 | -2.94% | 823,510 |
24-04-23 | 0.85 | 0.00% | 4,804,558 |
24-04-22 | 0.85 | 0.00% | 849,442 |
Delayed Quote London S.E., April 26, 2024 at 11:35 am
More quotes1st Jan change | Capi. | |
---|---|---|
-8.82% | 2.59M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- ONZ Stock